Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The bee, once widely found in the upper Midwest and Northeastern United States, was listed after U.S. President Donald Trump’s administration lifted a hold it had placed on a plan for federal protections proposed last fall by the administration of former President Barack Obama. Bumble bees are key pollinators of crops such as blueberries and cranberries, and are almost the only insect pollinator of tomatoes in the United States, according to the U.S. Fish and Wildlife Service. Conservation groups that had called for the new classification welcomed the move. “The listing helps mediate threats for this species and for all of those other animals out on the landscape that are suffering similar setbacks,” Rich Hatfield, senior biologist at the Xerces Society for Invertebrate Conservation, said by phone on Tuesday. The rusty patched bumble bee, or Bombus affinis, is one of 47 varieties of native bumble bees in the United States and Canada, more than a quarter of which face risk of extinction, according to the International Union for the Conservation of Nature. The population and range of the bee, named for the reddish blotch on its abdomen, have declined by more than 90 percent since the late 1990s due to disease, pesticides, climate change and habitat loss, according to wildlife officials. The agency in September proposed safeguarding the bee, but the listing was delayed by Trump’s White House as part of a broader freeze on rules issued by the prior administration. Environmental advocacy group the Natural Resources Defense Council sued last month, arguing that suspending the listing without public notice or comment violated the law. The NRDC said on Tuesday it was evaluating the next steps in its legal fight. Government scientists said the delay, part of a standard review, was not expected to affect the insect’s conservation, Interior Department spokeswoman Heather Swift said in a statement on Tuesday. The agency “will work with stakeholders to ensure collaborative conservation among landowners, farmers, industry, and developers in the areas where the species is native,” she added. Bumble bees pollinate wildflowers and about a third of U.S. crops, according to the Xerces Society. A recent study by the Center for Biological Diversity found that more than 700 of the 4,000 bee species native to North America and Hawaii may be inching toward extinction. Claim: First U.S. bumble bee added to endangered species list.

A: The rusty patched bumble bee became the first wild bee in the continental United States to gain federal protection on Tuesday when it was added to the government’s list of endangered and threatened species.
****
Q: Paragraph: A 38-year-old man from Zunyi city died last Thursday, Xinhua said, citing health authorities in Guizhou. Xinhua said it was the first human case of H7N9 in Guizhou this year. Last Friday, China said a 38-year-old man in eastern Fujian province died from H7N9. The World Health Organisation (WHO) said last week that seven more people in China had been found to be infected with the H7N9 strain of bird flu in the previous week, taking to around 150 the total number of cases so far. The H7N9 bird flu emerged last year in China and has infected around 150 people there and in Taiwan and Hong Kong, killing at least 45 of them. Experts say there is no evidence as yet of any easy or sustained person-to person transmission of the strain. But an early scientific analysis of probable transmission of the new flu from person to person, published last August, gave the strongest proof yet that it can at times jump between people and so could cause a human pandemic. The WHO said the source of the human infections was still being investigated. It stressed that it does not advise any special screening for people going in and out of China, nor does it recommend any travel or trade curbs. Claim: China reports second H7N9 bird flu death in a week.

A: China reported one more death from the H7N9 strain of bird flu in southwestern Guizhou province, state news agency Xinhua said on Monday, in the second death from the virus in the past week.
****
Q: Paragraph: The story does a good job of describing the monthly cost ($850) for women who do not have health insurance. The inference is that insurers will cover the cost for others. The story needed to include more information about the study results–in particular, how both the drug and the placebo performed in the trials. As we learn from the NEJM study, the drug reduced pain for about half of the women who took it–but the placebo also reduced pain for about 35% of the women who took it. That’s a good detail to include as it provides a better sense of the drug’s effectiveness. The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause. The double-blind, placebo-controlled trials are described, as are cautions, such as the short-term nature of the research. The reader will find ample information about the unpleasant symptoms of endometriosis. In some areas, it comes close to disease-mongering, when pointing out very rare instances of women needing many surgeries, or a case study of one woman having endometrial tissue in her nose. However, endometriosis is a medical condition, and often under-diagnosed, so we’ll rate this satisfactory. The scientist who led the two trials is clearly identified as such, but his consulting relationship with the company now marketing the drug is not mentioned, nor is the fact that that company, now positioned to benefit from selling the drug, paid for the studies. A number of existing pain-reduction alternatives are mentioned, from hormonal treatments to surgery, and their debits discussed. It would have been helpful to try and articulate how many women find the current alternatives insufficient. The text offers a likely date when this just-approved drug would become available at pharmacies. Although the research report describing the trials was published in The New England Journal of Medicine more than a year ago, this story is pegged to a more useful (to readers) “new event,” the US Food and Drug Administration’s approval of the drug. Abbvie, the company that funded the Stage 3 clinical trials of elagolix (brand name: Orilissa) and will now market the drug, made available an extensive news release on its web site. The Vox story contains a good bit of enterprise reporting and produced a story that is far more clear than the company’s effort. Claim: Women with endometriosis experience terrible pain. There’s finally a new treatment.

A:
The recent approval of a drug for the treatment of endometriosis pain is shared in this story in a way that satisfies many of our review site criteria. The story is carefully written, with lots of detailed explanations of the drug’s potential benefits — and drawbacks. Although some crucial information about funding and possible conflicts of interest is missing, the story otherwise affords the reader a readable and comprehensive “take” on the new drug. One clinical trial detail we think should have been included: The measured benefits for both the drug group and the placebo group. Endometriosis, a condition in which tissue migrates from the uterus into the abdomen of women, is relatively common and can be debilitatingly painful. While there is no cure at present, efforts to control the pain include hormonal treatments and even surgery, which produce their own complications. This story describes a new non-hormonal drug that appears to avoid some—but not all—of those complications.
****